Kwality Pharma Raises FY27 Revenue and Profit Guidance

Updated FY27 Guidance (vs. Previous Guidance and FY26 Actuals):

Revenue: Raised to INR 700+ Crore (previously INR 650 Crore), representing growth of +39%+ over FY26 revenue of INR 503 Crore.
EBITDA: Raised to INR 189-196+ Crore (previously INR 176-196 Crore), implying a margin of 27%-28%+ (previously 27%-28%). This is an increase of +13 basis points from the previous guidance and compares to an FY26 EBITDA of INR 118 Crore (~23.5% margin).
PAT: Raised to INR 109+ Crore (previously INR 100 Crore), implying a margin of ~15.5%+ (previously ~15.3%). This is an increase of +30 basis points from the previous guidance and compares to an FY26 PAT of INR 67 Crore (~13.4% margin).

Q1FY27 Financial Performance (YoY Growth):

Revenue from operations (Net): INR 162.4 Crore, a 45.7% increase from INR 111.5 Crore in the prior year period. Sequentially, revenue grew 3.4% from Q4FY26 (INR 157.1 Cr).
Profit after Tax (PAT): INR 25.7 Crore, a 119.3% increase from INR 11.9 Crore in the prior year period. Sequentially, PAT grew 3.2% from Q4FY26 (INR 24.9 Cr).

Manufacturing and Capacity:

The company operates manufacturing plants in Amritsar (Campus 1) and Himachal (Campus 2).
Overall capacity utilization has improved to ~65%+ from ~35%, a 1.9x increase.
4 out of 5 manufacturing plants are EU-GMP approved.
The company has successfully completed 20+ regulatory, customer, and vendor audits over the past two years.

Infrastructure Expansion:

A dedicated hormone manufacturing plant is under construction and is expected to commence operations by H2FY26.
Construction Status (as of Q1FY27): Civil Construction (50% complete), Equipment Procurement (80% complete), Equipment Installation (60% complete), Utilities & Services (10% complete), Team Recruitment (5% complete).
Key Milestones: Equipment order placed (Q3FY26), Major equipment installation (Q2FY27), Validation runs (Q2FY27), WHO GMP / PICS audit (Q3FY27), Commercial production (Q3FY27).
Initial Product Portfolio for New Unit: Over 40 products shortlisted across Sex Hormones and Synthetic Hormones in Injectable and OSD forms. Development has been initiated for 20+ injectable sex hormones.

R&D and New Platforms:

R&D spend has increased to ~2.5% of revenue from less than 1%.
The company is developing an end-to-end biologics platform. Pre-clinical success has been achieved for Erythropoietin.
The first biologic (Erythropoietin) is targeted for commercialization in H1FY28.
Core research initiatives include Biosimilars Development, Hypothesis driven innovation, Oncology Research, and Chronic Disease Research.
The biologics capacity is 300M injectables/year.
The company has 80 scientists in a DSIR-recognized team.
The updated FY27 guidance explicitly excludes contributions from the Hormone facility and Biologics platform, indicating potential upside.

Regulatory and Market Presence:

Cumulative filings have increased from 75 (FY23) to 700+ (FY26).
The company holds regulatory approvals from EU GMP, ANVISA (Brazil), INVIMA (Colombia), and others.
It operates in 70+ markets, exporting to LATAM, Africa, and MENA regions.

Balance Sheet Highlights (INR Crore):

| Particulars | FY23 | FY24 | FY25 | FY26 |

| Total Assets | 354 | 394 | 447 | 592 |

| Property Plant & Equipment | 120 | 139 | 144 | 150 |

| Capital Work in Progress | 14 | - | - | 17 |

| Inventories | 86 | 78 | 83 | 78 |

| Trade Receivables | 72 | 115 | 154 | 280 |

| Total Equity | 201 | 224 | 264 | 332 |

| Share Capital | 10 | 10 | 10 | 10 |

| Total Borrowings | 90 | 99 | 112 | 130 |

| Non-Current Borrowings | 27 | 20 | 15 | 29 |

| Current Borrowings | 63 | 79 | 97 | 101 |

Cash Flow Statement (INR Crore):

| Particulars | FY23 | FY24 | FY25 | FY26 |

| Cashflow from Operating Activities | 41.38 | 42.98 | 52.72 | 16.59 |

| Cashflow from Investing Activities | (48.44) | (26.39) | (28.52) | (34.90) |

| Cashflow from Financing Activities | 0.99 | (17.39) | (14.44) | 7.03 |

| Cash and Cash Equivalents (EoP) | 3.07 | 2.26 | 12.02 | 0.73 |

Operational Efficiency:

The working capital cycle has significantly improved, reducing from 297 days to 161 days.
The company is implementing secondary packaging tech transfers in international markets, with 10+ projects completed, to optimize logistics and costs.
Expected outcome includes a 300 bps margin improvement by FY27 and improved cost efficiency for market entry.

Ramesh Arora: Chairman & Managing Director (42 Years of Experience). Focus: IT, Software and Legal Agreements & Proceedings.
Ajay Arora: Director (31 Years of Experience). Focus: Raw material procurement and infrastructure development.
Aditya Arora: Director (11 Years of Experience). Focus: Quality assurance, Quality control, Regulatory compliance.